Imidafenacin

Drug Profile

Imidafenacin

Alternative Names: KRP 197; KRP-197OD; ONO 8025; ONO-8025OD; Staybla; Staybla OD Tablets; Uritos; Uritos OD Tablets

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Ajanta Pharma; Chong Kun Dang; Eisai Co Ltd; Kyorin Pharmaceutical; Ono Pharmaceutical
  • Class Imidazoles; Small molecules; Urologics
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder; Pollakisuria; Urinary incontinence
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Overactive bladder(Adjunctive treatment, Combination therapy) in Japan (PO, Fast dissolve)
  • 04 Oct 2016 Launched for Overactive bladder in Thailand (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pollakisuria in United Kingdom (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top